BIO Earnings & Financial Statements
Bio-Rad Laboratories, Inc.
$381.57
+$12.57(+3.41%)
61
Overall
60
Value
81
Tech
44
Quality
Market Cap
$10.26B
Volume
273.16K
52W Range
$236.73 - $396.23
Target Price
$368.67
BIO earnings and financial statements: Bio-Rad Laboratories, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
BIO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B |
| Cost of revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B |
| Operating income | $218.60M | $269.00M | $337.80M | $482.62M | $500.34M |
| EBITDA | $1.04B | -$2.29B | -$800.70M | -$4.67B | $5.59B |
| Net income | $759.90M | -$1.84B | -$637.30M | -$3.63B | $4.25B |
| EPS (diluted) | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.56 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $10.58B | $9.36B | $12.30B | $13.50B | $17.80B |
| Total liabilities | $3.12B | $2.79B | $3.56B | $3.89B | $4.11B |
| Shareholders’ equity | $7.45B | $6.57B | $8.74B | $9.62B | $13.69B |
| Cash and equivalents | $529.80M | $488.10M | $403.80M | $434.21M | $470.78M |
| Long-term debt | $1.35B | $1.33B | $1.36B | $1.35B | $186.45M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $532.20M | $455.20M | $374.90M | $194.40M | $669.46M |
| Capital expenditure | -$157.60M | -$165.50M | -$156.70M | -$114.30M | -$133.75M |
| Free cash flow | $374.60M | $289.60M | $218.20M | $80.10M | $535.72M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BIO | $381.57 | +3.4% | 273.16K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Bio-Rad Laboratories, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW